AbbVie lifts 2026 EPS guidance, closes Apogee deal, posts Skyrizi and Juvmo approvals
Third-quarter revenue rose 10.3 percent as AbbVie raised full-year adjusted EPS guidance and reported positive late-stage data in HS and DLBCL.
SEC filing (6)
3 stories
Third-quarter revenue rose 10.3 percent as AbbVie raised full-year adjusted EPS guidance and reported positive late-stage data in HS and DLBCL.
SEC filing (6)
BMS will not advance PRX019 in the clinic, ending a license tied to up to $617.5 million in potential milestones, Prothena said in an October 29, 2026 filing.
SEC filing
Chad J. Swanson, Ph.D. notified Prothena on October 2, 2026 that he is leaving effective October 9, 2026 to take a role at a strategic partner.
SEC filing